-
Media Release
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
-
Media Release
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
-
Media Release
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
-
Media Release
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
-
Media Release
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
-
Media Release
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
-
Media Release
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
-
Media Release
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
-
Media Release
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
-
Media Release
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
-
Media Release
Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a
-
Media Release
Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a